469
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

In vivo evaluation of monoclonal antibody M4M using a humanised rat model of stroke demonstrates attenuation of reperfusion injury via blocking human TRPM4 channel

, , , , , , & show all
Pages 413-422 | Received 09 Oct 2023, Accepted 23 Jan 2024, Published online: 12 Feb 2024

References

  • Nilius B, Prenen J, Droogmans G, et al. Voltage dependence of the Ca2+-activated cation channel TRPM4. J Biol Chem. 2003;278(33):30813–30820. doi: 10.1074/jbc.M305127200.
  • Mathar I, et al. Trpm4. Handb Exp Pharmacol. 2014;222:461–487.
  • Picardo MCD, Sugimura YK, Dorst KE, et al. Trpm4 ion channels in pre-Botzinger complex interneurons are essential for breathing motor pattern but not rhythm. PLoS Biol. 2019;17(2):e2006094. doi: 10.1371/journal.pbio.2006094.
  • Walcott BP, Kahle KT, Simard JM. Novel treatment targets for cerebral edema. Neurotherapeutics. 2012;9(1):65–72. doi: 10.1007/s13311-011-0087-4.
  • Loh KY, Wang Z, Liao P. Oncotic cell death in stroke. Rev Physiol Biochem Pharmacol. 2019;176:37–64.
  • Chen B, Ng G, Gao Y, et al. Non-Invasive multimodality imaging directly shows TRPM4 inhibition ameliorates stroke reperfusion injury. Transl Stroke Res. 2019;10(1):91–103. doi: 10.1007/s12975-018-0621-3.
  • Loh KP, Ng G, Yu CY, et al. TRPM4 inhibition promotes angiogenesis after ischemic stroke. Pflugers Arch. 2014;466(3):563–576. doi: 10.1007/s00424-013-1347-4.
  • Chen B, Wei S, Low SW, et al. TRPM4 blocking antibody protects cerebral vasculature in delayed stroke reperfusion. Biomedicines. 2023;11(5):1480. doi: 10.3390/biomedicines11051480.
  • Chen B, Gao Y, Wei S, et al. TRPM4-specific blocking antibody attenuates reperfusion injury in a rat model of stroke. Pflugers Arch. 2019;471(11-12):1455–1466. doi: 10.1007/s00424-019-02326-8.
  • Low SW, Gao Y, Wei S, et al. Development and characterization of a monoclonal antibody blocking human TRPM4 channel. Sci Rep. 2021;11(1):10411. doi: 10.1038/s41598-021-89935-5.
  • VanRyzin JW, Arambula SE, Ashton SE, et al. Generation of an Iba1-EGFP transgenic rat for the study of microglia in an outbred rodent strain. eNeuro. 2021;8(5):ENEURO.0026-21.2021. doi: 10.1523/ENEURO.0026-21.2021.
  • Pettibone JR, Yu JY, Derman RC, et al. Knock-In rat lines with cre recombinase at the dopamine D1 and adenosine 2a receptor loci. eNeuro. 2019;6(5):ENEURO.0163-19.2019. doi: 10.1523/ENEURO.0163-19.2019.
  • Bäck S, Necarsulmer J, Whitaker LR, et al. Neuron-Specific genome modification in the adult rat brain using CRISPR-Cas9 transgenic rats. Neuron. 2019;102(1):105–119.e8. doi: 10.1016/j.neuron.2019.01.035.
  • Ma Y, Yu L, Pan S, et al. CRISPR/Cas9-mediated targeting of the Rosa26 locus produces cre reporter rat strains for monitoring cre-loxP-mediated lineage tracing. Febs J. 2017;284(19):3262–3277. doi: 10.1111/febs.14188.
  • Percie Du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. Exp Physiol. 2020;105(9):1459–1466. doi: 10.1113/EP088870.
  • Walberer M, Stolz E, Müller C, et al. Experimental stroke: ischaemic lesion volume and oedema formation differ among rat strains (a comparison between wistar and Sprague-Dawley rats using MRI). p. Lab Anim. 2006;40(1):1–8. doi: 10.1258/002367706775404426.
  • Bederson JB, Pitts LH, Tsuji M, et al. Rat Middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17(3):472–476. doi: 10.1161/01.str.17.3.472.
  • Schattling B, Steinbach K, Thies E, et al. TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med. 2012;18(12):1805–1811. doi: 10.1038/nm.3015.
  • Wei S, Low SW, Poore CP, et al. Comparison of anti-oncotic effect of TRPM4 blocking antibody in neuron, astrocyte and vascular endothelial cell under hypoxia. Front Cell Dev Biol. 2020;8:562584. doi: 10.3389/fcell.2020.562584.
  • Satoh H, Delbridge LM, Blatter LA, et al. Surface:volume relationship in cardiac myocytes studied with confocal ­microscopy and membrane capacitance measurements: species-dependence and developmental effects. Biophys J. 1996;70(3):1494–1504. doi: 10.1016/S0006-3495(96)79711-4.
  • Wei S, Chen B, Low SW, et al. SLC26A11 inhibition reduces oncotic neuronal death and attenuates stroke reperfusion injury. Mol Neurobiol. 2023;60(10):5931–5943. doi: 10.1007/s12035-023-03453-1.
  • Wei S, Behn J, Poore CP, et al. Binding epitope for recognition of human TRPM4 channel by monoclonal antibody M4M. Sci Rep. 2022;12(1):19562. doi: 10.1038/s41598-022-22077-4.
  • Syam N, Rougier JS, Abriel H. Glycosylation of TRPM4 and TRPM5 channels: molecular determinants and functional ­aspects. Front Cell Neurosci. 2014;8:52. doi: 10.3389/fncel.2014.00052.
  • Mehta RI, Tosun C, Ivanova S, et al. Sur1-Trpm4 cation channel expression in human cerebral infarcts. J Neuropathol Exp Neurol. 2015;74(8):835–849. doi: 10.1097/NEN.0000000000000223.
  • Barbet G, Demion M, Moura IC, et al. The calcium-activated nonselective cation channel TRPM4 is essential for the migration but not the maturation of dendritic cells. Nat Immunol. 2008;9(10):1148–1156. doi: 10.1038/ni.1648.
  • Liao P, Loh KP. TRPM4 channel inhibitors for stroke treatment. US Patent. 2019;10,221,239.
  • Hazalin N, Liao P, Hassan Z. TRPM4 inhibition improves spatial memory impairment and hippocampal long-term potentiation deficit in chronic cerebral hypoperfused rats. Behav Brain Res. 2020;393:112781. doi: 10.1016/j.bbr.2020.112781.
  • Yu CY, Ng G, Liao P. Therapeutic antibodies in stroke. Transl Stroke Res. 2013;4(5):477–483. doi: 10.1007/s12975-013-0281-2.
  • Aghanejad A, Bonab SF, Sepehri M, et al. A review on targeting tumor microenvironment: the main paradigm shift in the mAb-based immunotherapy of solid tumors. Int J Biol Macromol. 2022;207:592–610. doi: 10.1016/j.ijbiomac.2022.03.057.